Morgan Stanley upgraded Globus Medical (GMED) to Overweight from Equal Weight with a price target of $100, up from $83, as the analyst assumed coverage of the stock. , The firm’s expectation is Globus’ AR headset will receive FDA clearance in Q4, noting that management plans to advance navigation with the headset as it is designed to work with ExcelsiusHub. Merger concerns are now “well behind us” and above market growth is expected to continue, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical launches ExcelsiusHub navigation system
- Globus Medical price target raised to $83 from $74 at Morgan Stanley
- Globus Medical price target raised to $92 from $80 at Stifel
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
- Globus Medical price target raised to $92 from $80 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com